Cytodyn Inc (CYDY)

[stockorus]

The stuff FDA says here is not something new. They are repeating the results and the lack of statistical significance for the full trial. They spent the biggest para there on CD10 and why it was not good enough, then a short one for CD12. We know that already. Then they mention the subgroup info and the possibility of further investigation. The letter is a remarkable undertaking of FDA to slap us for the pressure public put on behalf of an OTC company.

We know all they said, are focusing on the subgroup based on CD12 and other eIND data, and have already started probing opportunities elsewhere.

Were the sellers (or any of us) really thinking at this point that US FDA was about to approve LL that we are disappointed newly? No. Situation here is very different from getting Trial Results or Dilution. This is more about bad publicity (albeit from the biggest voice around) than actual new information. And Traders sell when the same news gets circulated in new ways that highlight bad; and FDA has given them a reason to save or make money by selling.

The real Trouble for us as others mentioned is that Brazil, India, Philippines are all going to see this formal letter from US FDA. Cytodyn has to be smart about controlling the negative impact of this letter in those places. Lets wait for what the company says.